2021 IGCS Business Meeting

Dear IGCS Members:

In accordance with Article III Section 3 of the International Gynecologic Cancer Society bylaws, we hereby notify all members of the upcoming Business Meeting of the Society.

The 2021 Business Meeting of the International Gynecologic Cancer Society will be held during the IGCS Annual Global Meeting on Tuesday, August 31 from 11:30 am – 12:00 pm CET in the Sinopoli Room at the Auditorium Parco della Musica in Rome, Italy.

IGCS Members joining us in Rome are encouraged to attend and it will be broadcast to our virtual audience simultaneously. Annual Global Meeting registration is required.

Topics discussed will include committee reports, the 2020 audited financial report, current membership data, an update from the International Journal of Gynecological Cancer, and new business. Click here to view the agenda.

If you would like to bring up new business, please contact me at mary.eiken@igcs.org prior to the meeting.

Sincerely,

Mary Eiken
IGCS CEO

Introducing IGCS COVID Safety Officer

Introducing IGCS COVID Safety Officer, Dr. Alessandro Cartelli

COVID-19 Health & Safety Guidelines and Requirements

  • Rapid testing is required for all delegates. Testing will be offered at the meeting venue on Sunday, August 29 and will remain available throughout the conference.
  • All meeting delegates must be tested by the IGCS COVID team and show a negative test result at the time of registration in order to enter the venue.

COVID-19 Health & Safety Guidelines and Requirements

  • Rapid testing is required for all delegates. Testing will be offered at the meeting venue on Sunday, August 29 and will remain available throughout the conference.
  • All meeting delegates must be tested by the IGCS COVID team and show a negative test result at the time of registration in order to enter the venue.
  • Face masks must be worn by all delegates at the congress while indoors as an extra safety precaution.
  • To accommodate social distancing at the Auditorium, a maximum of 500 in-person tickets will be sold. Seating within the halls has been spaced to adhere to social distance guidelines, currently 1m.
  • If a delegate tests positive for COVID-19, a molecular PCR test will be issued. If found positive, the delegate will not be allowed to enter the auditorium and will be advised on safe transportation from the auditorium to their hotel.

COVID-19 Health & Safety FAQ

Q: What Coronavirus-related safety precautions are being taken for meeting delegates in Rome?
A: IGCS is committed to the health and safety of our delegates, staff, and everyone who works at the meeting venue. We have been working closely with officials at the Auditorium, the local conference organizer, and receiving updates from the Italian government and we have implemented the following guidelines and procedures regarding COVID-19 safety.

Q: How many people will be able to attend in-person?
A: To accommodate social distancing at the Auditorium, a maximum of 500 in-person tickets will be sold.

Q: What is the COVID Safety Officer’s responsibility?
A: IGCS has appointed Dr. Alessandro Cartelli as COVID Safety Officer. He will be responsible for ensuring that guidelines are followed, and proper steps are taken in the event of a positive COVID case. For questions, please email Dr. Cartelli.

Q: What testing will be required to be admitted to the meeting venue?
A: Our onsite team will be conducting rapid testing with the STANDARD Q COVID-19 Ag Test by SD BIOSENSOR.  It is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2 present in human nasopharynx, approved by the Italian and European FDA and is valid for the screening of this population. The specimen is collected though a nasopharyngeal swab. Test results will be available after 15 minutes and those who test negative will proceed to registration to collect their Congress information.

Q: When will I need to be tested?
A: All meeting delegates must be tested by the IGCS COVID team and show a negative test at the time of registration. Testing will be offered at the meeting venue on Sunday, August 29, 2021 and will remain available throughout the conference.

Q: Is IGCS testing required if I recently completed testing somewhere else?
A: Yes, the test done by IGCS is required. COVID tests that have been done elsewhere and Green passes issued in the EU will not be accepted to grant access to the Congress. All delegates must have a negative test performed by the IGCS team at the venue. IGCS is covering the cost of the required COVID test for entry.

Q: What if I am not in Rome on August 29th to get tested by the IGCS team?
A: Testing stations will be available throughout the duration of the meeting.

Q: What happens if I test positive for COVID-19?
A: If a delegate tests positive for COVID-19, a molecular PCR test will be issued. If found positive, the delegate will not be allowed to enter the auditorium and will be advised on safe transportation from the auditorium to their hotel. The IGCS COVID team will provide them with information and assistance on local medical care and further testing facilities as needed. Note that any required PCR testing and transportation away from the venue will be at the expense of the delegate. The delegate will receive a registration conversion from an in-person pass to a virtual pass and will receive the appropriate refund in price in adherence to the IGCS registration conversion and cancellation policy.

Q: What are the current safety measures in place at The Auditorium?
A: The Auditorium has provided detailed safety measures that will be shared with delegates attending in-person in advance of the meeting. At this time, guidelines include but are not limited to:

  • Temperature checks upon entering the Auditorium.
  • All those entering the Auditorium will be required to wear an FFP2 face mask at all times while in the Auditorium.   
  • Seating within the halls has been spaced to adhere to social distance guidelines, currently 1m. A maximum of 500 delegates will be allowed.
  • Notices stating safety regulations to be followed, aimed principally at the audience, will be displayed at various points inside the Auditorium.

Q: Is there any information that I need to be aware of regarding COVID-19 and travel?
A: Click here for important information from the Italian Ministry of Health regarding travel and COVID-19. This includes specific information about the classification of territories, travel restrictions, rules, and requirements for travelling to and from abroad.

IGCS 2021 Presidential Plenary

In this video message, Dr. Coleman reveals that this year’s Presidential Plenary will focus on current clinical trials and international efforts to work cooperatively, ensuring research dedicated to women’s cancers continues to advance globally.

The Presidential Plenary will be held on Tuesday, August 31 at 2:10pm Central European Time.

During the plenary, invited guests from the GOG – (Gynecologic Oncology Group Partners) and ENGOT – (the European Network for Gynaecological Oncological Trial Group) will share the latest information and relevant clinical trials in progress. These groups operate through global partnerships and emulate so much of how the IGCS operates day in and day out… through the success of partnerships and international collaboration.

 

2nd International Web Conference

Thursday, May 20, 2021
5:00 - 2:00 EDT (New York)
12:00 - 21:00 MSK (Moscow)

The IGCS in collaboration with the American Eurasian Cancer Alliance (AECA) and the Russian Reproductive Tumor Society invite you to participate in the 2nd International Web-Conference “Gynecologic oncology: from clinical trials to practice” with the key topic of discussion, "Rare Gynecologic Tumors."

As part of a full meeting agenda, AECA-affiliated experts from University of Toronto, MD Anderson Cancer Center, Johns Hopkins University, Memorial Sloan Kettering, and N.N. Blokhin National Medical Research Center will discuss a range of topics related to research, diagnosis, and treatment of ovarian, endometrial, vulvovaginal, and cervical cancers, with a particular emphasis on rare cases. Leaders from Blokhin will also present on surgical management of germ cell tumors of the ovary. The event is open to the global gynecological cancer community. 

Reports, discussions and interactive sessions will be dedicated to the following topics:

  • Rare Malignant Gynecologic Tumors
  • Minimally Invasive and Open Surgical Procedures in Gynecologic Oncology
  • Innovations in diagnostics and treatment of gynecologic malignancies

Program Outline

5:00 – 7:00  EDT - New York / 12:00 – 14:00 MSK - Moscow
Russian Reproductive Tumors Society`s Session (Language: Russian)
Innovations in Diagnostics and Treatment of Gynecologic Malignancies

7:00 – 8:45 EDT - New York / 14:00 – 15:45 MSK - Moscow
Surgical Session (Language: Russian)
Minimally Invasive and Open Procedures in Gynecologic Oncology

9:00 - 2:00 EDT -New York / 16:00 – 21:00 MSK - Moscow
International Session (Language: English with simultaneous translation)
Case Based Reviews of Rare Gynecologic Cancers

Pathology Session
Chairs: Anna Plotkin (Canada),  Apollon Karseladze (Russia)

Ovarian Cancers Session
Chairs: Amanda Fader (USA), Kirill Zhordania (Russia)

Endometrial Cancers Session
Chairs: Michael Frumovitz (USA), Yulia Paianidi (Russia)

Vulvovaginal and Cervical Cancers
Chairs: Pedro Ramirez (USA), Alexey Shevchuk (Russia)

GCIG CCRN Grant Opportunity for LMICs

The Gynecologic Cancer InterGroup (GCIG), Cervix Cancer Research Network (CCRN) is announcing a call for proposals to support small research initiatives which are aimed to improve the outcomes for women with cervical cancer in low- and middle-income countries (LMICs) where the disease is a burden and where national research groups are not yet established.

Visit the GCIG website, gcigtrials.org for the latest information.

Details:

  • The award amount will be up to $5000 USD.
  • Candidates affiliated with a CCRN site will be given priority.
  • Any successful candidate, if not already affiliated with a CCRN site, will be expected to have their site join CCRN by completing the CCRN pre-qualifying questionnaire (PQQ).

Criteria:

  1. candidates will be clinicians in LMIC’s, who treat women with cervical cancer;
  2. the research proposals will be assessed and approved by the CCRN Executive Committee;
  3. all research proposals related to the management of women with cervical cancer will be considered and include (but not exclusive to):
    – Retrospective analysis
    – Prospective studies
    – Translational research
    – Quality of Life research
    – Palliative care
    – Radiation quality assurance
  4. the candidate is expected to publish the results of the research funded by this grant

Applicant Contact Information:
Name:
Medical/Research Institute:
Email address:
Phone Number:

  • Please attach research proposal, budget and cv of principle investigator
  • Include evidence of Good Clinical Practice (GCP) training.
  • For those unfamiliar with GCP, we will provide links for online training platforms.

Submit application to:
Katherine Bennett, GCIG-CCRN Operations Manager, +1 613 539-6456
cervixcancerresearchnetwork@gmail.com

 

Watch: WHO Cervical Cancer Elimination Launch Nov 17

The WHO is launching its Global Strategy to Accelerate the Elimination of Cervical Cancer on November 17, 2020. 

Main event (Part I):
14:30 to 16:00 CET (Geneva)

Webinar (Part II): New technical materials to support implementation
16:15 to 17:45 CET (Geneva)

Click here to visit the WHO website to learn about the program, watch the live stream and register for the webinar.

2021 Membership Renewal

It’s that time of year! If your membership is set to expire on December 31st, please make sure to renew so that we may continue to serve you in 2021.

On behalf of the IGCS leadership, I want to thank all of you in advance for paying your 2021 membership dues. We know you have other organizations that you belong to and IGCS is very grateful for your willingness to continue your membership with us. Dues allow organizations, like IGCS, to fund important programs that are essential to you, our members, and for you to take advantage of the many member benefits offered.

IGCS, being a member driven organization, relies on the members to support us in many ways – including renewing your membership.

Please sign in to your member account and submit your membership dues for 2021 or pay in advance up to three years. If you have questions or need assistance, please contact the IGCS Membership Manager, Cathy Fearing at cathy.fearing@igcs.org.

As always, we thank you for your continued dedication. We look forward to serving you for another year!

Mary Eiken, MS
IGCS CEO

IGCS 2020 Meeting Access

To access the IGCS 2020 xDigital Annual Global Meeting Portal, go to 2020.igcsmeeting.com

 

Registered Delegates: Your unique access code was sent via email in a message from icrossing@igcsmeeting.com with the subject line “IMPORTANT: DELEGATE PASS – IGCS xDigital.”

If you cannot find the email message with your access code, please check your spam filter first.
If you cannot locate the message, please email help@igcsmeeting.com

💬 Help and support

A dedicated email and live chat will be available to delegates 24 hours a day throughout the congress for any assistance or queries that arise. Access the live chat through the Help and Support page on 2020.igcsmeeting.com when the congress portal is open or email us at help@igcsmeeting.com.

🖥️ Browser Requirements

The browsers listed below are compatible with the congress portal:
• Windows: Edge 12+, IE 11+, Firefox 27+, Chrome 30+
• Mac: Recommended: Chrome 30+ (Safari is not supported)
• Linux: Firefox 27+, Chrome 30+

💻 Operating System Requirements

Check your computer’s operating system before the start of the congress to ensure the software works with the congress portal. See below list of compatible operating systems:
• MacOS X with macOS 10.7 or later
• Windows 10*, 8.1, 8, 7
• Red Hat Enterprise Linux 6.4 or higher
• iOS 7.0 or later
• iPadOS 13 or later
• Android 4.0x or later

*Windows 10 Home, Pro or Enterprise only. S Mode is not supported.

Symposium – Desktop device
We recommend viewing the symposium on your desktop device for the best experience.

Disclaimer
The xDigital platform is a unique, custom-built environment that leverages a number of different technologies. One of these technologies is Zoom. Please check your company usage policies if you are using company equipment to access the congress. If Zoom is prohibited, you will need to request special dispensation to use it, or arrange an alternative device.

IGCS 2020 Abstract Graders

Abstract and Surgical Film Submission for the IGCS 2020 Annual Global Meeting closed on July 15, 2020 at 11:59 pm PDT. We are grateful to have received over 500 abstracts and acknowledge our volunteer graders for their time reviewing and grading all of the abstracts in our expedited timeline.

IGCS 2020 Abstract Graders

Angeles Alvarez Secord, USA
Annika Auranen, Finland
Line Bjorge, Norway
Donal Brennan, Ireland
Al Covens, Canada
Carien Creutzberg, Netherlands
Greta Dreyer, South Africa
Andreas du Bois,  Germany
Keiichi Fujiwara, Japan
Thomas Herzog, USA

Anuja Jhingran, USA
Rainer Kimmig, Germany
Brad Monk, USA
Sara Nasser, Germany
Farr Nezhat, USA
Remi Nout, Netherlands
Andreas Obermair, Australia
Marie Plante, Canada
Francesco Plotti, Italy

Matt Powell, USA
Eric Pujade Lauraine, France
Isabelle Ray-Coquard, France
Ritu Salani, USA
Giovanni Scambia, Italy
Jalid Sehouli, Germany
Alexey Shevchuk, Russia
Alejandro Soderini, Argentina
David Tan, Singapore

Late Breaking Abstracts
Late breaking abstracts (LBAs) will be accepted from July 25-August 15. LBAs should contain new information that was not available at the time of the general abstract deadline.
Learn more about abstract submission.

Learn more about the innovative xDigital platform by viewing this video demo.

IJGC Impact Factor & Readership Survey

We are delighted to share the 2019 impact factor for the International Journal of Gynecological Cancer of 2.095 (Journal Citation Reports, Clarivate Analytics), which ranked 41/82 in the Obstetrics and Gynecology category and 195/244 in the Oncology category.

IGCS congratulates IJGC Editor-in-Chief, Dr. Pedro Ramirez and the entire Editorial Team for the success of the journal and expanded reach. Their efforts are certainly evident in the transformation of the journal with new features and article types promoting research in the field of gynecologic cancer all over the world.

The quality and impact of journals are dependent on many different measures. IJGC has provided some of those metrics for International Journal of Gynecological Cancer, to reflect the latest 2019 data. Click here to view top most cited articles from each of the last two years, free to read.

Journal Metrics

Speed
Days to first decision: 16
Days from acceptance to publication: 29

Impact
2 year Impact Factor (JCR): 2.095
SciMago Journal Rank (SJR): 1.011
Eigenfactor: 0.01217
Citescore: 3.8

Reach
2019 total Content accesses: 310,000
Altmetric score: 2,688

Readership Survey (July 2020)

The International Journal of Gynecological Cancer is conducting a readership survey to collect feedback from IGCS members and subscribers regarding journal content and educational offerings such as podcasts, video articles and different article types. Please complete the survey here.